Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Share-based Compensation (2021 - 2025)

Biote (BTMD) has 5 years of Share-based Compensation data on record, last reported at $2.4 million in Q3 2025.

  • For Q3 2025, Share-based Compensation rose 7.35% year-over-year to $2.4 million; the TTM value through Sep 2025 reached $8.6 million, down 2.68%, while the annual FY2024 figure was $8.7 million, 3.56% down from the prior year.
  • Share-based Compensation reached $2.4 million in Q3 2025 per BTMD's latest filing, up from $2.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $79.3 million in Q2 2022 and bottomed at $47000.0 in Q1 2022.
  • Average Share-based Compensation over 5 years is $5.9 million, with a median of $2.1 million recorded in 2022.
  • Peak YoY movement for Share-based Compensation: soared 87009.89% in 2022, then crashed 96.66% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $82000.0 in 2021, then soared by 2539.02% to $2.2 million in 2022, then decreased by 7.72% to $2.0 million in 2023, then fell by 5.56% to $1.9 million in 2024, then rose by 27.78% to $2.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $2.4 million in Q3 2025, $2.2 million in Q2 2025, and $2.1 million in Q1 2025.